Castle Biosciences
The firm is hoping that growing real-world evidence for DecisionDx-Melanoma will support better clinical recognition as it continues to expand its menu.
Castle Biosciences Q1 Revenues Grow 18 Percent
The Friendswood, Texas-based molecular diagnostics company reported revenues of $26.9 million in Q1 2022, up from $22.8 million a year ago.
Omics Tools and MDx Stocks Down Across the Board in April, Following Broader Market
The GenomeWeb Top 40 was down 12 percent in April, while the Dow Jones, Nasdaq, and Nasdaq Biotech Index were down 5, 13, and 10 percent, respectively.
Castle Biosciences, VHA Expand Supply Contract to Cover Full Skin Cancer Test Portfolio
The new contract with the Veterans Health Administration makes all five of the company's skin cancer assays available for veterans, active-duty military, and family members.
In Brief This Week: Natera, Caris Life Sciences, Fulgent Genetics, Castle Biosciences, More
News items for the week of April 25, 2022
Apr 5, 2022
Castle Biosciences to Acquire AltheaDx for $65M
Feb 28, 2022
Castle Biosciences Q4 Revenues Grow 45 Percent
Nov 8, 2021
Castle Biosciences Q3 Revenues Rise 54 Percent
Oct 27, 2021
Aug 9, 2021
Castle Biosciences Q2 Revenues Rise 79 Percent
May 11, 2021
May 10, 2021